Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Heart Failure Clinical Trial

— HALO-Shock  

Official title:

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04419480
• Other study ID #: U19-05-3608
• Status: Recruiting
• Phase: N/A
• Start date: December 31, 2020
• Est. completion date: December 31, 2026

Study information

• Verified date: February 2024
• Source: Inova Health Care Services
• Contact: Shashank Sinha, MD MSc
• Phone: 7037764001
• Email: shashank.sinha[@]inova.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pilot Prospective Randomized Unblinded Pragmatic Trial of Pulmonary Artery Hemodynamic Monitoring Following Hospitalization for Cardiogenic Shock

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject or legal representative has signed Informed Consent Form (ICF) and the patient has the capacity to participate in the study and complete the study questionnaires, in the estimation of the study investigator.

2. Age = 18 years

3. NYHA Class III with dyspnea upon mild physical activity, regardless of left ventricular ejection fraction (LVEF).

4. Survive to discharge during a current hospital admission with cardiogenic shock (CS) as defined by clinical criteria previously used in cardiogenic shock trials: systolic blood pressure < 90 mmHg for > 30 minutes or requiring infusion of catecholamines to maintain the systolic blood pressure above 90 mmHg, with evidence of end-organ dysfunction such as pulmonary edema or impaired end-organ perfusion including altered mentation, oliguria with urine output < 30 mL/h, or serum lactate > 2 mmol/L (5). Hemodynamic criteria include cardiac index = 1.8 L/min/m2 without vasoactive pharmacologic agents, or cardiac index = 2.2 L/min/m2 and pulmonary artery occlusion pressure = 15 mmHg with vasoactive agents.

5. Patients must have internet and phone access (to allow communication of the implanted device with the researchers).

Exclusion Criteria:

1. Technical obstacles which pose an inordinately high procedural risk, in the judgment of the investigator.

2. Treatment with ongoing mechanical circulatory support (MCS) such as a durable left ventricular assist device (LVAD) or recipient of a heart transplantation for the treatment of cardiogenic shock during the index hospitalization for CS.

3. If of childbearing potential with a positive pregnancy test.

4. Transition to hospice care.

5. Intolerance to or inability to adhere to antiplatelet therapy for 1 year after device implantation.

6. Presence of an active, uncontrolled infection.

7. Any condition other than heart failure that could limit survival to less than 6 months

8. Discharge to facility other than acute rehabilitation or to the ambulatory setting.

9. No access to internet or phone.

Related Conditions & MeSH terms

• Ambulatory Hemodynamic Monitoring
• Cardiogenic Shock
• Heart Failure
• Shock
• Shock, Cardiogenic

Intervention

Device:
• CardioMEMS implantation with routine ambulatory pulmonary artery pressure monitoring and medication optimization
Implantation of CardioMEMS Device in patients following admission for Cardiogenic shock, with regular ambulatory pulmonary artery pressure monitoring and medication optimization for the treatment of heart failure.

Locations

Country	Name	City	State
United States	Inova Fairfax Medical Campus	Falls Church	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
Inova Health Care Services	Abbott

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hierarchical primary endpoint	Hierarchical endpoint at 6-months, including death (or mortality-equivalent including left ventricular assist device implantation or heart transplantation), recurrent cardiovascular hospitalization, health related quality of life change from baseline, measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ) as a continuous score, and change in log-transformed NT-proBNP level from enrollment to 6 months, evaluated by the win ratio according to the Finkelstein-Schoenfeld method	6 months
Secondary	Health related quality of life change from baseline	Health related quality of life change from baseline, measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ) as a continuous score at 2 months and 6 months following admission for CS.hemodynamic monitor is safe in the high-risk CS population.	2 months and 6 months
Secondary	All-cause mortality	All-cause mortality from enrollment.	6 months
Secondary	All-cause mortality or cardiovascular hospitalization	Time to first all-cause mortality or cardiovascular hospitalization.	6 months
Secondary	All-Cause Hospitalization	Time to all-cause hospitalization.	6 months
Secondary	Unscheduled hospital visits (including Emergency Department and Outpatient Diuretic Infusion Clinic)	Time to all unscheduled hospital visits (including Emergency Department and Outpatient Diuretic Infusion Clinic)	6 months
Secondary	Change in NT-pro-B-type natriuretic peptide (NT-pro-BNP)	Change in NT-pro-B-type natriuretic peptide (NT-pro-BNP) from enrollment to 6 months follow up.	6 months
Secondary	Achieved guideline directed medical therapy for heart failure	Achieved guideline directed medical therapy for heart failure with reduced ejection fraction at 6 months, measured by achievement of >50% of the guideline targeted optimal dosing of angiotensin receptor blocker or angiotensin converting enzyme inhibitor or angiotensin receptor neprilysin inhibitor, beta-blocker, and mineralocorticoid receptor antagonist.	6 months
Secondary	Safety of early post-discharge implantation of a pulmonary artery hemodynamic monitoring.	Safety of early post-discharge implantation of a pulmonary artery hemodynamic monitor in the high-risk CS population, including device-related or system-related complications or pressure-sensor failures.	6 months